Nomoto, Hiroshi
Kito, Kenichi
Iesaka, Hiroshi
Handa, Takahisa
Yanagiya, Shingo
Miya, Aika
Kameda, Hiraku
Cho, Kyu Yong
Takeuchi, Jun
Nagai, So
Sakuma, Ichiro
Nakamura, Akinobu
Atsumi, Tatsuya
Article History
Received: 23 July 2023
Accepted: 12 October 2023
First Online: 26 October 2023
Declarations
:
: The study was approved by the institutional review board of Hokkaido University Hospital (018–0440), and informed consent was obtained from all participants.
: Not applicable.
: Nomoto H, Sakuma I, Nakamura A, and Atsumi T have received honoraria for lectures and research funding from the organizations listed below. Nomoto H received research grants from Kowa Pharmaceutical Co., Ltd., and honoraria for lectures from Novo Nordisk Pharma and Sumitomo Pharma Co., Ltd. Sakuma I received research grants from Kowa Pharmaceutical Co., Ltd. Nakamura A has received research support from Mitsubishi Tanabe Pharma, Daiichi Sankyo, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Life Scan Japan, and Taisho Pharmaceutical Co., Ltd. TA received research grants from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Alexion Inc., Ono Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.; speaking fees from Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb Co., UCB Japan Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., and Taisho Pharmaceutical Co., Ltd; and fees for consultancies from AstraZeneca plc., Medical & Biological Laboratories Co., Ltd., Pfizer Inc., AbbVie Inc., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Nippon Boehringer Ingelheim Co., Ltd. The other authors declare no conflict of interest.